Work overview

Section 07 of 09

Ethics Statement

Complement‐Dominant Relapse of Mixed Autoimmune Hemolytic Anemia After Rituximab Response

Naru Tomigaki, Seiji Kakiuchi, Akimasa Sakamoto, Shutaro Fujioka, Isamu Harima, Hiroaki Akiyama, Ryotaro Niwa, Ikumi Takagi, Yoko Kozuki, Yoshiharu Miyata, Sou Tanaka, Hiroyuki Tsuji, and Nobuko Iwata · 2026

Contents

Section 07 of 09

  1. 01Introduction
  2. 02Case Presentation
  3. 03Discussion
  4. 04Conclusion
  5. 05Section 5
  6. 06Funding
  7. 07Ethics Statement
  8. 08Consent
  9. 09Conflicts of Interest
Text size
Work overview

Section 7 of 9

Ethics Statement

Naru Tomigaki, Seiji Kakiuchi, Akimasa Sakamoto, Shutaro Fujioka, Isamu Harima, Hiroaki Akiyama, Ryotaro Niwa, Ikumi Takagi, Yoko Kozuki, Yoshiharu Miyata, Sou Tanaka, Hiroyuki Tsuji, and Nobuko Iwata · about 1 minutes

Original source ↗

Off‐label rituximab treatment was approved by the institutional review board of Yodogawa Christian Hospital (approval number: 2025‐007). Sutimlimab was administered within its approved indication in Japan and did not require separate institutional review board approval.